Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: A possible interaction between donor and recipient genetic polymorphisms

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 4, 2013, Pages 333-336

  Quaglia, M ^a   Terrazzino, S ^a   Boldorini, R ^a   Stratta, P ^a   Genazzani, A A ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

calcineurin inhibitor nephrotoxicity; genetic polymorphism; renal transplant; tacrolimus

Indexed keywords

BASILIXIMAB; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HEMODIALYSIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY;

CALCINEURIN INHIBITOR NEPHROTOXICITY; GENETIC POLYMORPHISM; RENAL TRANSPLANT; TACROLIMUS;

CYTOCHROME P-450 CYP3A; GENOTYPE; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 84879992639     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12066     Document Type: Article

References (30)

1. Iwasaki K,. Metabolism of Tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet, 2007; 22: 328-335.
2. Kershner RP, Fitzsimmons WE,. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation, 1996; 62: 920-926.
3. Anglicheau D, Flamant M, Schlageter MH, et al,. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant, 2003; 18: 2409-2414.
4. Gijsen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN,. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Tranplant, 2012; 17: 111-121.
5. Haehner BD, Gorski JC, Vandenbranden M,. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol, 1996; 50: 52.
6. Bolbrinker J, Seeberg S, Schostak M, Kempkensteffen C, Baelde H, de Heer E, Kreutz R,. CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele. Drug Metab Dispos, 2012; 40: 639-641. doi: 10.1124/dmd.111.042648. Epub 2012 Jan 3.
7. Tang HL, Xie HG, Yao Y, Hu YF,. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics, 2011; 21: 713-720.
8. Joy MS, Hogan SL, Thompson BD,. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant, 2007; 22: 1963.
9. Metalidis C, Lerut E, Naesens M, Kuypers DRJ,. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Transplantation, 2011; 91: 1098-1102.
10. Ding X, Kaminsky LS,. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol, 2003; 43: 149-173.
11. Elens L, van Schaik RH, Panin N, et al,. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics, 2011; 12: 1383-1396.
12. Elens L, Bouamar R, Hesselink DA, et al,. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem, 2011; 57: 1574-1583.
13. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W,. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J, 2011; 11: 274-286.
14. Karpinski J, Lajoie G, Cattran D, et al,. Outcome of Kidney Transplantation From High-Risk Donors Is Determined By Both Structure and Function. Transplantation, 1999; 8: 1162-1167.
15. Tsunoda SM, Aweeka FT,. The use of therapeutic drug monitoring to optimize immunosuppressive therapy. Clin Pharmacokinet, 1996; 30: 107-140.
16. Stratta P, Quaglia M, Cena T, et al,. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol, 2012; 68: 671-680.
17. Boldorini R, Allegrini S, Miglio U, et al,. BK virus sequences in specimens from aborted fetuses. J Med Virol, 2010; 82: 2127-2132.
18. Hu YF, He J, Chen GL,. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta, 2005; 353: 87-92.
19. Wu L, Xu X, Shen J, et al,. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol, 2007; 96: 62-68.
20. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y,. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit, 2010; 32: 394-404.
21. Glowacki F, Lionet A, Buob D, et al,. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant, 2011; 26: 3046-3050.
22. Iwasaki K, Shiraga T, Masuda H, et al,. Further metabolism of FK 506 (Tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK 506. Drug Metab Dispos, 1995; 23: 28-34.
23. Kuypers DR, de Jonge H, Naesens M, et al,. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine the long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther, 2007; 82: 711-725.
24. Shimada T, Terada A, Yokogawa K, et al,. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation, 2002; 74: 1419-1424.
25. Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF,. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy, 2005; 25: 779-789.
26. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet, 2010; 49: 141-175.
27. Hauser IA, Schaeffeler E, Gauer S, et al,. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol, 2005; 16: 1501-1511.
28. Yamauchi A, Ieiri I, Kataoka Y, et al,. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation, 2002; 74: 571-572.
29. Anglicheau D, Thervet E, Etienne I, et al,. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther, 2004; 75: 422-433.
30. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA,. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet Genomics, 2012; 22: 642-645.